Non-infectious cystitis as a complication of toripalimab therapy in a patient with alpha-fetoprotein-producing gastric adenocarcinoma: a case study
Background
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for gastric cancer, yet they can lead to rare immune-related adverse events (irAEs), including those affecting the urinary system. Non-bacterial cystitis is a particularly uncommon irAE, and its occurrence in patients with alpha-fetoprotein-producing gastric carcinoma (AFP-GC) is not well-documented.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
A 59-year-old male with AFP-GC developed non-bacterial cystitis and acute kidney injury after toripalimab and SOX chemotherapy.
Symptoms included urinary tract irritation, gross hematuria, and stage II acute kidney injury.
Cystoscopy revealed diffuse mucosal hemorrhage, and biopsy showed extensive lymphocyte infiltration and high PD-L1 expression.
Healthcare professionals should monitor for urinary-related irAEs in patients undergoing treatment with ICIs, particularly in rare subtypes like AFP-GC.
Conclusion
This case highlights non-bacterial cystitis as a potential complication of ICI therapy in gastric cancer patients.